Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are associated with biliary damage and graft survival in a case-control study - 29/01/20

páginas | 11 |
Iconografías | 5 |
Vídeos | 0 |
Otros | 0 |
Highlights |
• | Biliary calprotectin, dimeric pyruvate kinase and lactoferrin are early markers for irreversible, progressive biliary damage after liver transplantation. |
Summary |
Background |
After liver transplantation (LT), biliary complications are associated with reduced graft survival. We tested inflammation markers for their association with biliary damage and graft loss in bile.
Material and methods |
The study design was a retrospective case-control study. Calprotectin, lactoferrin and pyruvate kinase were measured in endoscopically retrieved bile with ELISA.
Results |
Calprotectin and lactoferrin were significantly higher in bile of ischemic-type biliary lesions and donor duct non-anastomotic strictures than in control, bile leakage, Cytomegalovirus infection, anastomotic stricture or acute cellular rejection patients (p<0.001) independent of serum liver values at endoscopy. Calprotectin (p=0.02) was independently associated with retransplantation free survival in multivariate analysis, as was γGT (p=0.03) but not ERC radiographic classification of the bile duct or cold ischemia time.
Conclusion |
Calprotectin and lactoferrin are bile markers for biliary damage and are associated with re-transplantation free survival. They can differentiate progressive biliary damage from non-biliary liver value alterations after LT.
El texto completo de este artículo está disponible en PDF.Keywords : Calprotectin, Lactoferrin, Pyruvate kinase, Liver transplantation, Rejection, Biliary stricture
Abbreviations : αHBc, ACR, ALAT, AP, AS, ASAT, CMV, CRP, ddNAS, ERC, γGT, IBD, IBS, INR, ITBL, ELISA, LT, M2PK, NAS
Esquema
Vol 44 - N° 1
P. 38-48 - février 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?